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Summary This randomised phase II study was performed in order to evaluate the effectiveness of a weekly
chemotherapy regimen in advanced prostatic carcinoma patients (stage D2) refractory to hormonal therapy.
Seventy-two cases were studied: they were randomised in a 2:1 ratio to receive either epirubicin (30 mgm 2
weekly) or doxorubicin (25 mg m weekly); 48 patients received epirubicin and 24 received doxorubicin.
After 12 courses of chemotherapy, the 45 evaluable patients in the epirubicin arm showed a response rate of
37.7% and the 21 evaluable patients in the doxorubicin arm showed a response rate of 33.3% (P = 0.51)
Pain intensity, bone and prostatic tumour markers rapidly and significantly decreased in responders. An
improvement in physical symptoms, functional conditions and in emotional well-being was observed in the
majority of the treated patients.
The histological analysis of bone metastases, performed before and after 12 courses of chemotherapy
showed a significant reduction in neoplastic invasion and in new bone formation in responders.
Cardiac performance worsened in five out of 45 patients and in ten out of 21 during the first 12 courses of
epirubicin or doxorubicin respectively (P = 0.014).
The median survival was 12.5 months in the epirubicin arm and 8.0 months in the doxorubicin arm
(P = 0.042).
Our data indicate that in advanced prostatic carcinoma, a weekly epirubicin regimen may give rapid
palliative results, similar to that of doxorubicin, but with less side-effects.
Prostatic cancer is a common neoplasm in which the results
of treatment remain somewhat controversial. Both surgery
and radiation therapy have potentially curative roles, pro-
vided the tumour is confined to the prostate itself. However,
once lymphnodes are involved, the possibility of dissemina-
tion is high. The usual sites of distant metastases include the
skeleton, liver and lungs.
Hormonal therapy remains a standard and effective syste-
mic approach to disseminated disease (Klein, 1979; Fossa et
al., 1990; Sharifi et al., 1990).
Patients who fail to respond to hormonal treatment, or
relapse after an initial response should be considered for
chemotherapy. Among antineoplastic agents, doxorubicin
appears to be one of the best single agents for prostatic
cancer, but its cardiotoxicity limits its use especially in this
aged patient group and consequently, alternatives are desir-
able (Dewys et al., 1977; Von-Hoff et al., 1982).
In the past decade, Torti et al. (1983) reported that a
weekly regimen with low doses of doxorubicin, instead of the
conventional one on a 3-week basis, is able to strongly reduce
side effects, particularly cardiotoxicity. Subsequently, pre-
liminary studies with epirubicin (the 4'-epimer of doxoru-
bicin) have suggested that this new anthracycline derivative is
less cardiotoxic than doxorubicin while achieving similar
antitumor effects (Torti et al., 1986; Francini et al., 1989). It
is therefore reasonable to assume that a weekly schedule with
epirubicin could further decrease anthracycline-induced side
effects and the risk of cardiotoxicity. The aim of the study
was to test this hypothesis in prostatic cancer relapsed after
hormonal therapy.
Skeletal metastases in prostatic cancer are usually osteo-
blastic, and make the assessment of response to treatment
particularly difficult. This is one of the major problems in
monitoring advanced prostatic cancer; very often different
methods and criteria of response evaluation have produced
conflicting results. Currently, the most widely used response
criteria are those of National Prostatic Cancer Project
(NPCP) (Slack & Murphy, 1984), but these criteria are
insufficient for monitoring the turnover of osteoblastic bone
metastases. In fact, radiographic resolution of osteoblastic
lesions is rare, while the detection of scintigraphic changes
requires careful attention to technical details of scanning
(Levenson et al., 1983).
Patients and methods
Patient selection
We studied 72 subjects with advanced prostatic adenocarcin-
oma (stage D2) who relapsed after hormonal therapy in a
period ranging from 1985 to 1990. Patients who did not
respond to first line hormonal therapy were excluded. All of
the patients had bone metastases identified by radiography
and r['Te]-methylene diphosphonate bone scan. The main
characteristics of the patients are shown in Table I.
Randomisation and treatment
Based on the expectation that epirubicin would have less
cardiotoxicity and myelotoxicity than doxorubicin, our Ethi-
cal Committee approved a randomisation in a ratio of two
epirubicin subjects to one doxorubicin: 48 patients were
assigned to receive epirubicin, 30 mg m-2 i.v. weekly, and 24
to receive doxorubicin 25 mg m-2 i.v. weekly. Variables were
similarly distributed in the two groups.
The chemotherapy was continued until progression of the
disease occurred or until major side-effects developed. When
chemotherapy was stopped, the patients received only the
best supportive care. No patient was under active treatment
with hormonal therapy during the period of chemotherapy.
No patient had been pretreated with chemotherapy, radio-
therapy, or calciotropic drugs.
Patients were considered evaluable for response and tox-
icity only after they had undergone at least six courses of
chemotherapy.
Radiological
Skeletal survey, chest X-ray and liver echography were per-
formed every six courses, and bone scan every 12 courses. A
complete physical examination was performed every week.
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Blood and urine parameters
It is well-known that the early effects of treatment on the
morphologic evaluation of bone metastases cannot be detect-
ed by bone scans or X-ray; for early detection, one must rely
on the measurement of biochemical indices both of tumour
cell proliferation and of bone turnover (Ahmann et al., 1987;
Francini et al., 1988; Coleman, 1991; Francini et al., 1992).
Thus, the following parameters were evaluated in all subjects,
before the start of chemotherapy, after three, six, nine, and
12 courses, and then every 2 months.
- Serum acid phosphatase (Acid Ph.), a significant marker
in prostatic cancer (Reif et al., 1973), was measured by
means of the acid phosphatase test (Sclavo, Siena, Italy) -
normal values (n.v.): 1.1-3.4KAU.
- Prostatic specific antigen (PSA) and prostatic acid phos-
phatase (PAP), useful markers of prostatic cancer
(Ahmann et al., 1987), were measured by the immuno-
radiometric method (Diagnostic Products Corporation,
Los Angeles, USA)- n.v.: 0-4 ng ml-' and 0.6-4.3 ng
ml-' respectively.
- 24 h whole body retention (WBR%) of [99mTc]-methylene
diphosphonate, an index of bone turnover and particular-
ly elevated in pagetoid metastases of prostatic cancer, was
calculated according to Caniggia & Vattimo (1980)- n.v.:
33.3 ± 7.4 (%).
- Serum bone Gla-protein (BGP), which reflects osteoblas-
tic activity (Price et al., 1981), was measured by radio-
immunoassay (RIA) (Incstar Corporation, Stillwater,
Minnesota, USA)- n.v.: 3-8 ng ml-'.
- Serum alkaline phosphatase (Alk.Ph.) commonly in-
creased in sclerotic bone metastases (Wajsman et al.,
1978), was measured by the ALP-Kline Test Kit (Sclavo,
Siena, Italy), according to the method of King & Arm-
strong modified by Bessey et al. (1946) - n.v.: 4-13
KAU.
- 24 h urinary hydroxyproline excretion (UHOP), an index
of osteoclastic activity (Immergut et al., 1966), was
measured by Prockop & Udenfriend method (1960) -
n.v.: 10-40 mg 24 h-'. All values of urinary hydroxypro-
line were expressed as a function of urinary creatinine
excretion - n.v. UHOP/Cr ratio = 25 ± 7.2 mg g-'.
The following parameters were measured at weekly inter-
vals: complete blood cell count, pain intensity and perfor-
Table I Main characteristics of patients
Total cases = 72 Epirubicin Doxorubicin
Enrolled patients 48 24
Evaluable patients 45 21
Median age (range) 65 (50-74) 63 (53-72)
Performance status (ECOG)
1 3 2
2 19 7
3 23 14
4 3 1
Predominant metastatic sites:
Bone
Viscera
Soft tissue
Prior treatment:
Orchiectomy
Orchiectomy + antiandrogens
LH-RH agonists
+antiandrogens
LH-RH agonists only
Antiandrogens only
Median duration of response to
hormonal treatment (months)
Baseline biochemistry (mean ±s.e.)
PSA (ng ml-')
PAP (ng ml-')
Acid Ph. (KAU)
Alk.Ph. (KAU)
BGP (ng ml ')
UHOP/Cr (mg g-')
WBR (%)
34
9
S
3
8
27
15
6
3
2
4
10
6
2
8
2
14 (7-24) 12 (9-22)
(173 ± 28)
(38 ± 6)
(48 ± 7)
(58 ± 5)
(18 ±2)
(59± 5)
(66± 5)
(191 ± 25)
(39± 5)
(51 ± 3)
(55 ± 3)
(16± 1)
(64± 5)
(64±4)
Table II National prostatic cancer project (NPCP) response criteria
(from: Slack, N.H. & Murphy, G.P.: Urol. Clin. North Am., 11,
337-342, 1984)
Partial response - any offollowing:
1. Recalcification of one or more of any osteolytic lesions.
2. A reductionby 50% in the numberofincreaseduptake areas on the
bone scan.
3. Decrease of50% or more in cross-sectional area ofanymeasurable
lesions.
4. Ifhepatomegaly is a significant indicator, there must be at least a
30% reduction in liver size indicated by a change in the
measurements, and at least a 30% improvement of all pretreated
abnormalities of liver function including bilirubin mg dl-' and
SGOT.
All of the following:
5. No new sites of disease.
6. Acid phosphatase returned to normal.
7. No deterioration in weight (<10%), symptoms or performance
status.
Objective stable - all ofthefollowing:
1. No new lesions occurred and no measurable lesions increased more
than 25% in cross-sectional area.
2. Elevated acid phosphatase, ifpresent, decreased, though need not
have returned to normal.
3. Osteolytic lesions, ifpresent, did not appear to worsen.
4. Osteoblastic lesions, ifpresent, remained stable on the bone scan.
5. Hepatomegaly, ifpresent, did not appear to worsen bymore than a
30% increase in the measurements, and symptoms of hepatic
abnormalities did not worsenincluding bilirubinmg% and SGOT.
Objective progression - any ofthefollowing:
1. Significant cancer related deterioration in weight (>10%), symp-
toms, or performance status.
2. Appearance of new areas of malignant disease by bone scan or
X-ray or in soft tissue by other appropriate techniques.
3. Increaseinanypreviouslymeasurablelesionbygreaterthan25% in
cross-sectional area.
4. Development of recurring anaemia, secondary to prostatic cancer
(not chemotherapy).
5. Development of ureteral obstruction.
TableIII Modificationsadded totheNPCPcriteria(Slack&Murphy,
1984)
Partial remission
(added criteria)
- All of the following, exclusively for osteoblastic metastases:
* reduction of more than 50% of bone (WBR%, BGP, Alk.Ph.,
UHOP/Cr) and prostatic tumour markers (Acid Ph., PAP, PSA);
* disappearance of pain;
* performance status returned to normality;
* reduction ofless than 50% in the number ofuptake areas by bone
scan.
Progression
(added criteria)
- Increase of more than 50% of bone and prostatic tumour markers.
mance status. The pain intensity was evaluated by means of
the Scott & Huskisson visual analogue scale (1976), and the
performance status using the ECOG scale.
Response assessment
The most widely used response criteria are those of NPCP
(Table II). An overall evaluation of the responses was made
according to modified NPCP group criteria; the modifica-
tions added by us are shown in Table III.
Only the patients who achieved a partial remission were
considered 'responders'.
Histological
Histological analysis of bone metastases was performed using
transiliac bone biopsy specimens in patients with extensive
lesions of the basin: (i) 20 patients before starting epirubicin
and then in 12 responders after 12 courses; (ii) ten patients
before starting doxorubicin and in five responders after 121432 G. FRANCINI et al.
courses (Faugere & Malluche, 1983). The results, before and
after chemotherapy, in terms of neoplastic invasion and of
new bone formation, were compared by the methods of
Weibel (1979) and Frost (1969).
Toxicity and quality oflife
Toxicity was evaluated according to World Health Organiza-
tion (WHO) criteria (1979).
The systolic indices of cardiac performance were measured
by the use of pre-ejection period/left ventricular ejection time
(PEP/LVET), according to Hassan & Turner (1983) (PEP/
LVET ratio in a normal adult (0.35 in our laboratory).
Treatment was delayed if the leukocytes were <2,500
mm 3, platelets <50,000, bilirubin >3 mg dl-' and if the
PEP/LVET ratio increased to > 10% of normal values. Dur-
ing the first 12 courses of chemotherapy, a maximum delay
of 1 week was allowed; thereafter, a maximum delay of 3
weeks was allowed. In case of lower values of leukocyte and
platelet count and in case of congestive heart failure, treat-
ment was discontinued. No dose reductions were made.
To assess quality of life, patients completed a question-
naire regarding physical symptoms, functional activity, family
and emotional well-being, treatment satisfaction and occupa-
tional functioning on a weekly basis.
Statistics
Statistical analyses of biochemical measurements were per-
formed using the Student's t test for paired samples, compar-
ing pretreatment vs post-treatment values in both responding
and non-responding patients.
Response rates were compared by Fisher's exact test; a P
value of 0.05 was assumed to indicate statistical significance.
Survival curves were determined by the Kaplan & Meier
method (1958) and further comparisons based on the log-
rank statistics (Peto et al., 1977). Data were collected and
analysed with the aid of statistical analysis software (Release
1.1 Level 2 for Digital VAX/UMS, December 23, 1986, SPSS
Inc. 444, North Michigan Avenue, Chicago, IL 60611, USA).
Results
All of the 72 eligible patients were evaluated for survival and,
of these, 66 were evaluable for response and toxicity: 45
receiving epirubicin and 21 receiving doxorubicin. The
median number of administered courses was 16 for the
epirubicin arm (range 4-38) and nine for the doxorubicin
arm (range 3-25).
The response rate in epirubicin-treated patients (17/45:
37.7%) (95% confidence limit; 23% to 50%) was similar to
the doxorubicin group (7/21: 33.3%) (94% confidence limit;
13% to 53%) (P = 0.51) (Table IV).
Performance status showed a rapid improvement in all
responding patients and in the majority of those who
achieved stable disease. These patients had a notable im-
provement in physical symptoms, such as bone pain, weak-
ness and anorexia, in functional conditions, such as capacity
to work and to enjoy one's free time, and in emotional well
being. Most of the patients showed treatment satisfaction.
The bone markers (WBR%, BGP, Alk Ph, UHOP/Cr) and
the prostatic tumour markers (Acid Ph., PAP, PSA) showed
a significant reduction in all patients defined as responders
both in the epirubicin and doxorubicin arm (Figure 1). The
Table IV Response to treatment after 12 courses of epirubicin or
doxorubicin
Response criteria Epirubicin (n = 45) Doxorubicin (n = 21)
Partial remission (PR) 17 7
Stable disease (SD) 19 8
Progression (P) 5 3
Died 4 3
PR 37.7% 33.3%
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Figure 1 Mean responses±standard errors for 24 h whole body
retention (WBR%), bone Gla-protein (BGP), serum alkaline
phosphatase (Alk.Ph.), urinary hydroxyproline/creatinine ratio
(UHOP/Cr), pain intensity (VAS), serum acid phosphatase (Acid
Ph.), prostatic acid phosphatase (PAP) and prostatic specific
antigen (PSA) in patients defined responders during 12 courses of
epirubicin (A) or doxorubicin (x). 'P value' shows the signifi-
cant difference between values pretreatment with post treatment.
(*P < 0.05; **P < 0.01; ***P < 0.001). (--- Upper limit of nor-
mal range).
aforementioned markers showed a progressive increase in
patients defined as non responders (Figure 2).
After 12 courses of chemotherapy, five patients in partial
remission (four epirubicin and one doxorubicin) showed
recalcification of at least one osteolytic lesion with no change
in the osteoblastic bone metastases. Seven patients with par-
tial remission (five epirubicin and two doxorubicin) showed a
50% regression in the cross-sectional area of the predom-
inant metastatic site (lung) and stabilisation of bone metas-
tases with at least 50% reduction in levels of bone (WBR%,
BGP, Alk Ph, UHOP/Cr) and prostatic tumour markers
(Acid.Ph., PAP, PSA). Twelve cases with exclusively osteo-
blastic metastases (eight epuribicin and four doxorubicin)
showed a reduction <50% in uptake areas on the bone scan
and a reduction of more than 50% in the levels of bone and
prostatic tumour markers with disappearance of pain and
significant improvement in performance status.
Using the NPCP criteria alone, there were 9/45 (20%)
responders in the epirubicin arm and 3/21 (14.8%) in the
doxorubicin arm. This difference was not statistically signi-
ficant (P = 0.46).
The histological analysis of the transiliac bone biopsy spec-
imens showed a significant reduction both of neoplastic inva-
sion and new bone formation in six out of 12 patients after
12 courses of epirubicin and in two out of five patients after
12 courses of doxorubicin (Figure 3, al vs a2).
The median duration ofpartial remission in epirubicin and
doxorubicin-treated patients was similar (10.8 months vs 8.8;
P= 0.35).
At the end of 24 months of follow-up (range 12-65), the
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Figure 2 Mean responses ±standard errors for 24 h whole body
retention (WBR%), bone Gla-protein (BGP), serum alkaline
phosphatase (Alk.Ph.), urinary hydroxyproline/creatinine ratio
(UHOP/Cr), pain intensity (VAS), serum acid phosphatase (Acid
Ph.), prostatic acid phosphatase (PAP) and prostatic specific
antigen (PSA) in patients defined non responders during 12
courses of epirubicin (A) or doxorubicin (x). 'P value' shows
the significant difference between values pretreatment with post
treatment. (*P < 0.05; **P < 0.01; ***P < 0.001).
survival rate in 48 patients receiving epirubicin was 73%
after 6 months, 54% after 12 months, and 29% after 18
months, with an overall median survival of 12.5 months
(range 1.5-24+). The survival rate in 24 patients receiving
doxorubicin was 58% after 6 months, 29% after 12 months,
and 4% after 18 months, with an overall median survival of
8.0 months (range 1.5-21). The difference between the two
survival curves was significant (P= 0.042) (Figure 4).
Toxicity
Toxicity is summarised in Table V. The predominant adverse
effects of chemotherapy were mainly cardiotoxicity and mye-
lotoxicity. The PEP/LVET ratio increased significantly in five
out of 45 patients (11.1%) in the epirubicin arm and in ten
out of 21 (47.6%) in the doxorubicin arm during the first 12
courses of chemotherapy (P = 0.014). The PEP/LVET ratio
increased significantly in two patients in the epirubicin arm
and in four in the doxorubicin arm during three further
courses. Clinical congestive heart failure was not observed in
patients receiving epirubicin, while it occurred in four
patients receiving doxorubicin between the 9th and 13th
course.
Grade 2-3 leukopenia occurred in eight out of 45 patients
receiving epirubicin (17.7%) and in 11 out of 21 receiving
doxorubicin (52.3%) after 12 courses of chemotherapy (P=
0.03).
Grade 2-3 anaemia was observed in seven out of 45
patients receiving epirubicin (15.5%) and in 12 out of 21
receiving doxorubicin (57.1%) after 12 courses of chemo-
therapy (P = 0.01).
Nausea was rarely observed in both treatment groups and
was less severe in the epirubicin arm (in which no grade 3,
Table V Number of patients showing toxicity
Side effects Epirubicin (n = 45) Doxorubicin (n = 21)
Leukopenia
WHO grade 1 28 6
WHO grade 2-3 8 11
WHO grade 4 0 1
Thrombocytopenia
WHO grade 1 6 5
WHO grade 2-3 2 3
Anaemia
WHO grade 1 29 5
WHO grade 2-3 7 12
Stomatitis
WHO grade 1-2 5 4
Nausea-vomiting
WHO grade 1-2 10 15
WHO grade 3 0 2
Alopecia
WHO grade 1 40 8
WHO grade 2-3 5 11
WHO grade 4 0 2
Infection
WHO grade 1 14 10
WHO grade 2-3 7 5
Haemorrhagic cystitis 2 2
Cardiotoxicity
(PEP/LVET 10%) 5 10
Toxic deaths 0 0
four grade 2 and six grade 1 were recorded vs two grade 3,
six grade 2 and nine grade 1 in the doxorubicin arm).
Grade 2-3 hair loss occurred in five epirubicin treated
patients and 11 doxorubicin treated patients after 12 courses
of chemotherapy. Complete alopecia was observed in only
two patients in the doxorubicin arm.
Chemotherpay was delayed during the first 12 courses in
16 patients (five epirubicin and 11 doxorubicin) because of
cardiotoxicity and myelosuppression. After 12 courses, 24
patients (14 epirubicin and ten doxorubicin) required repeat-
ed delays because of toxicities. Treatment was discontinued
after 12 courses in seven patients (two epirubicin and five
doxorubicin) because of cardiotoxicity and/or persistent mye-
losuppression.
Discussion
Systemic chemotherapy studies in advanced prostatic cancer
have been few and have obtained mixed results (Torti et al.,
1983; Eisenberger & Abrams, 1988; Francini et al., 1989).
This is partly due to the excessive length of previous hor-
monal therapy or radiotherapy and partly to the poor res-
ponsiveness of prostatic neoplastic cells to the most common
antiproliferative agents. In addition, many patients are
elderly, anaemic, and in pain from bone metastases which
causes decreased mobility, thus, making monitoring in out-
patients difficult. Considering that all the patients in this
study were in an advanced stage of the disease (stage D2),
the effectiveness of our weekly schedule of chemotherapy
appears to be satisfactory. However, it must be noted that
chemotherapy was immediately started when bone and pros-
tatic tumour markers showed a significant increase and
before a decrease in performance status occurred.
It is notable that chemotherapy (epirubicin or doxorubicin)
achieved a rapid palliative response with improvement in
bone pain. The quality of life, which is the major endpoint
for evaluating the effectiveness of a treatment, improved in
most of the patients, and many of them were free to carry
out their daily activities. Moreover, bone markers (WBR%,
BGP, Alk Ph, UHOP/Cr) and prostatic tumour markers
(Acid Ph., PAP, PSA) dropped significantly in responsive
patients.
Considering the great difficulties involved in the assessment
of response criteria in advanced prostatic cancer, the use of
bone and prostatic tumour markers, together with other
evaluation criteria such as performance status, bone pain and1434 G. FRANCINI et al.
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Figure 3 An example of histopathology of transiliac bone biopsy specimens in one patient: (a,) before and (a2) after 12 courses of
chemotherapy. (a,) x 100: Nests of neoplastic cells occupy the bone marrow space, which is regularly lined by osteoblastic/
osteoclastic cells. The lamellar organisation appears of irregular woven texture. (a2) x 160: The neoplastic proliferation appears less
aggressive and a desmoid reaction is observable. The osteoblastic/osteoclastic cells are less evident and the lamellar texture is more
regular.
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tic factor has been described that stimulates both DNA
results obtained with the weekly synthesis, and osteoblastic and fibroblastic prolifera-
ful to focus on some characteris- tion.
Thus, the significant reduction in bone pain and in the
levels of bone and prostatic tumour markers during chemo-
therapy is probably due to a reduction in number and/or
activity of the tumour cell populations (Francini et al., 1988;
Scher et al., 1990; Hussain et al., 1991; Francini et al., 1992).
This is also supported by the histopathology of bone biopsy,
which demonstrated a significant reduction in invading neo-
plastic cells and in new bone formation in responders. Regarding cardiac toxicity, only five patients receiving
epirubicin showed a significant increase in the PEP/LVET
m ma ratio without cardiac failure during 12 courses; in one of
these cases, the PEP/LVET ratio reverted spontaneously to
baseline 20 days after withdrawal of treatment. In another
b _ four patients, a considerable improvement was observed after
pharmacological treatment with non-digitalis inotropic agents
12 18 24 (Neri et al., 1988). Conversely, ten patients receiving doxo-
Months rubicin showed an increase of PEP/LVET during the first 12
courses, and of these four had clinical congestive heart
a, 48 patients treated with epiru- failure.
loxorubicin. Leukopenia and serious anaemia were observed in fewerWEEKLY CHEMOTHERAPY IN PROSTATIC CANCER 1435
cases in the epirubicin arm compared with the doxorubicin
arm. In these cases, cytotoxic treatment had to be delayed for
a week or more, and the patients needed repeated blood
transfusions. However, these side effects were not always
linked to drug myelotoxicity; in fact, decreases in haemo-
globin levels, which are an extremely important prognostic
parameter, often reflected the metastatic invasion of bone
marrow or uraemic marrow suppression and sometimes urin-
ary blood losses (Berry et al., 1979; Newling, 1985). Never-
theless, chemotherapy alone produced an improvement of the
bone marrow reserve in at least 11 patients.
As to the comparative efficacy of the two anthracyclines,
our findings suggest a similar response rate of epirubicin vs
doxorubicin after 12 courses (37.7% vs 33.3%) and a signi-
ficantly longer survival (median: 12.5 vs 8.0 months). The
difference in cardiotoxicity and myelotoxicity between the
two treatment arms and consequently the longer duration of
treatment probably accounts for the better survival seen in
patients receiving epirubicin. However, this significant differ-
ence may represent a false-positive observation due to the
limited number of patients studied.
In conclusion, our data indicate that in patients with
advanced prostatic cancer who have relapsed after hormonal
therapy a weekly epirubicin regimen may give rapid palliative
results, similar to that of doxorubicin, but with fewer side
effects.
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